Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Merger with Schering-Plough to Make Merck 8th Company in Japan
March 15, 2010
- New NHI Prices Applicable from April 1 Announced
March 15, 2010
- 12 Generics Priced Higher Than Their Originals
March 15, 2010
- Group Organized to Increase Awareness of COPD
March 15, 2010
- Price Reduction Rate Lowest for Eli Lilly, Highest for Chemiphar
March 15, 2010
- Don't Create Any More New Medical Schools: AJMC
March 15, 2010
- Astellas to Enhance Oncology Pipeline through TOB of OSI
March 15, 2010
- Double-Digit Price Cuts for 27 Products from 35 Leading Companies
March 15, 2010
- 3 Candidates for JMA President Election
March 15, 2010
- Pfizer Japan: Sales Up 2.6% despite Fall in Sales of Norvasc
March 15, 2010
- Premium Will Be Effective for Expediting Development of New Drugs, Indications: Mr Nagatsuma
March 15, 2010
- Shionogi Licenses Ospemifene from QuatRx
March 15, 2010
- Toyobo's Sales to Top ¥400 Bil. in FY2015 Driven by Life Science Business
March 15, 2010
- Korosho Starts Hearing Major Chain Pharmacy Operators
March 15, 2010
- EFPIA Japan to Work to Eliminate Drug Lag
March 15, 2010
- Astellas Withdraws Application for Diabetic Incipient Nephropathy for Micardis
March 15, 2010
- Teijin Licenses SB623 from SanBio
March 15, 2010
- Korosho to Prepare for 2nd Round of Screening by GRU
March 15, 2010
- 2009 Sales of Ethical Drugs Up 7.2% to ¥8,851.6 Bil.: IMS Japan
March 15, 2010
- Takeda to Initiate PIII Trials for Lu AA21004, Lu AA24530 in the US
March 15, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…